A1 Journal article (refereed)
Effect of Omega-3 Dosage on Cardiovascular Outcomes : An Updated Meta-Analysis and Meta-Regression of Interventional Trials (2021)
Bernasconi, A. A., Wiest, M. M., Lavie, C. J., Milani, R. V., & Laukkanen, J. A. (2021). Effect of Omega-3 Dosage on Cardiovascular Outcomes : An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo Clinic Proceedings, 96(2), 304-313. https://doi.org/10.1016/j.mayocp.2020.08.034
JYU authors or editors
Publication details
All authors or editors: Bernasconi, Aldo A.; Wiest, Michelle M.; Lavie, Carl J.; Milani, Richard V.; Laukkanen, Jari A.
Journal or series: Mayo Clinic Proceedings
ISSN: 0025-6196
eISSN: 1942-5546
Publication year: 2021
Volume: 96
Issue number: 2
Pages range: 304-313
Publisher: Elsevier
Publication country: United States
Publication language: English
DOI: https://doi.org/10.1016/j.mayocp.2020.08.034
Research data link: https://ars.els-cdn.com/content/image/1-s2.0-S002561962030985X-mmc1.pdf
Publication open access: Openly available
Publication channel open access: Partially open access channel
Publication is parallel published (JYX): https://jyx.jyu.fi/handle/123456789/71911
Abstract
Methods:This study is designed as a random effects meta-analysis and meta-regression of ran-domized control trials with EPA/DHA supplementation. This is an update and expanded analysis ofa previously published meta-analysis which covers all randomized control trials with EPA/DHAinterventions and cardiovascular outcomes published before August 2019. The outcomes includedare myocardial infarction (MI), coronary heart disease (CHD) events, CVDevents (a composite ofMI, angina, stroke, heart failure, peripheral arterial disease, sudden death, and non-scheduledcardiovascular surgical interventions), CHD mortality and fatal MI. The strength of evidence wasassessed using the Grading of Recommendations Assessment, Development, and Evaluationframework.
Results:A total of 40 studies with a combined 135,267 participants were included. Supplementationwas associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certaintynumber needed to treat (NNT) of 272; CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certaintyNNT of 192; fatal MI (RR, 0.65; 95% CI, 0.46 to 0.91]), moderate certainty NNT¼128; and CHDmortality (RR, 0.91; 95% CI, 0.85 to 0.98), low certainty NNT¼431, but not CVD events (RR, 0.95;95% CI, 0.90 to 1.00). The effect is dose dependent for CVD events and MI.
Conclusion:Cardiovascular disease remains the leading cause of death worldwide. Supplementationwith EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effectprobably increases with dosage.
Keywords: omega fatty acids; health effects; cardiovascular diseases; meta-analysis
Free keywords: omega-3 dosage; cardiovascular outcomes
Contributing organizations
Ministry reporting: Yes
Reporting Year: 2021
JUFO rating: 2
